PriceTargets.com logo

Nuvalent - NUVL Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $137.86
  • Forecasted Upside: 29.01%
  • Number of Analysts: 15
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 14 Buy Ratings
  • 0 Strong Buy Ratings
$106.86 As of 12/4/2025 05:00 PM ET
▼ -0.04 (-0.04%)

This chart shows the closing price for NUVL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Nuvalent Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NUVL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NUVL

Analyst Price Target is $137.86
▲ +29.01% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for Nuvalent in the last 3 months. The average price target is $137.86, with a high forecast of $158.00 and a low forecast of $105.00. The average price target represents a 29.01% upside from the last price of $106.86.

This chart shows the closing price for NUVL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 15 polled investment analysts is to moderate buy stock in Nuvalent. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 1 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 1 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/9/2024
  • 1 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
6/7/2025
  • 1 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 13 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 14 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 14 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/24/2025Truist FinancialSet Target$140.00
11/24/2025Truist FinancialInitiated CoverageBuy$140.00
11/18/2025The Goldman Sachs GroupBoost TargetBuy ➝ Buy$120.00 ➝ $135.00
11/18/2025Robert W. BairdBoost TargetOutperform ➝ Outperform$112.00 ➝ $158.00
11/18/2025GuggenheimBoost TargetBuy ➝ Buy$125.00 ➝ $155.00
11/17/2025BarclaysSet Target$152.00
11/17/2025WedbushReiterated RatingOutperform$120.00 ➝ $125.00
11/17/2025Stifel NicolausBoost TargetBuy ➝ Buy$115.00 ➝ $135.00
11/17/2025Leerink PartnersBoost TargetOutperform ➝ Outperform$140.00 ➝ $149.00
11/17/2025HC WainwrightBoost TargetBuy ➝ Buy$130.00 ➝ $155.00
11/12/2025Canaccord Genuity GroupInitiated CoverageBuy$126.00
10/31/2025The Goldman Sachs GroupReiterated RatingBuy ➝ Buy$120.00
10/31/2025UBS GroupBoost TargetBuy ➝ Buy$114.00 ➝ $132.00
10/31/2025BarclaysBoost TargetOverweight ➝ Overweight$100.00 ➝ $112.00
10/27/2025Piper SandlerBoost TargetOverweight ➝ Overweight$112.00 ➝ $128.00
10/16/2025Stifel NicolausInitiated CoverageBuy$115.00
10/15/2025Cantor FitzgeraldInitiated CoverageOverweight$135.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/8/2025WedbushReiterated RatingOutperform ➝ Outperform$115.00
9/4/2025GuggenheimInitiated CoverageBuy$122.00
9/2/2025Raymond James FinancialInitiated CoverageOutperform$105.00
8/19/2025Piper SandlerInitiated CoverageOverweight$112.00
7/21/2025WedbushReiterated RatingOutperform$115.00
6/30/2025The Goldman Sachs GroupUpgradeStrong-Buy
6/25/2025Robert W. BairdBoost TargetOutperform ➝ Outperform$105.00 ➝ $112.00
6/24/2025WedbushReiterated RatingOutperform$115.00
6/24/2025Leerink PartnersBoost TargetOutperform ➝ Outperform$125.00 ➝ $140.00
6/24/2025HC WainwrightReiterated RatingBuy ➝ Buy$110.00 ➝ $130.00
3/14/2025UBS GroupUpgradeNeutral ➝ Buy$100.00 ➝ $100.00
3/3/2025HC WainwrightReiterated RatingBuy ➝ Buy$110.00 ➝ $110.00
1/17/2025HC WainwrightReiterated RatingBuy ➝ Buy$110.00 ➝ $110.00
1/13/2025WedbushReiterated RatingOutperform$115.00
12/30/2024HC WainwrightInitiated CoverageBuy$110.00
11/13/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$132.00 ➝ $134.00
11/12/2024WedbushReiterated RatingOutperform$115.00
10/24/2024UBS GroupInitiated CoverageNeutral$100.00
10/4/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$100.00 ➝ $125.00
9/16/2024The Goldman Sachs GroupUpgradeStrong Sell
9/16/2024WedbushBoost TargetOutperform ➝ Outperform$99.00 ➝ $115.00
9/16/2024GuggenheimBoost TargetBuy ➝ Buy$99.00 ➝ $105.00
9/16/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$102.00 ➝ $132.00
9/16/2024Stifel NicolausBoost TargetBuy ➝ Buy$115.00 ➝ $135.00
9/9/2024WedbushReiterated RatingOutperform ➝ Outperform$99.00 ➝ $99.00
9/4/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$90.00 ➝ $100.00
8/29/2024BarclaysInitiated CoverageOverweight$100.00
8/22/2024WedbushReiterated RatingOutperform$9.00
8/8/2024WedbushReiterated RatingOutperform$99.00
7/29/2024Lifesci CapitalUpgradeStrong-Buy
7/22/2024WedbushReiterated RatingOutperform$99.00
7/10/2024Stifel NicolausBoost TargetBuy ➝ Buy$103.00 ➝ $115.00
5/17/2024WedbushReiterated RatingOutperform ➝ Outperform$99.00
4/17/2024Jefferies Financial GroupInitiated CoverageBuy$97.00
4/1/2024Leerink PartnrsUpgradeMarket Perform ➝ Outperform
4/1/2024Leerink PartnersUpgradeMarket Perform ➝ Outperform$69.00 ➝ $110.00
3/6/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$68.00 ➝ $98.00
2/28/2024BMO Capital MarketsBoost TargetOutperform ➝ Outperform$93.00 ➝ $102.00
2/28/2024GuggenheimInitiated CoverageBuy$99.00
2/27/2024WedbushReiterated RatingOutperform$99.00
2/23/2024Robert W. BairdInitiated CoverageOutperform$105.00
2/22/2024Leerink PartnrsReiterated RatingMarket Perform
2/12/2024WedbushReiterated RatingOutperform$82.00 ➝ $99.00
1/8/2024WedbushReiterated RatingOutperform$74.00 ➝ $82.00
11/14/2023WedbushReiterated RatingOutperform$74.00
10/19/2023BMO Capital MarketsBoost TargetOutperform ➝ Outperform$73.00 ➝ $79.00
10/5/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$51.00 ➝ $68.00
10/5/2023BMO Capital MarketsBoost TargetOutperform ➝ Outperform$52.00 ➝ $73.00
10/4/2023WedbushBoost Target$53.00 ➝ $65.00
10/4/2023Stifel NicolausReiterated RatingBuy
9/26/2023Stifel NicolausInitiated CoverageBuy$65.00
9/11/2023WedbushReiterated RatingOutperform$53.00
8/10/2023WedbushReiterated RatingOutperform$53.00
8/8/2023Leerink PartnrsReiterated RatingMarket Perform
8/8/2023Leerink PartnersInitiated CoverageMarket Perform$42.00
8/8/2023SVB SecuritiesInitiated CoverageMarket Perform$42.00
7/24/2023GuggenheimInitiated CoverageBuy$56.00
7/20/2023WedbushReiterated RatingOutperform ➝ Outperform$53.00
1/17/2023WedbushInitiated CoverageOutperform$39.00
10/28/2022BMO Capital MarketsBoost TargetBuy$28.00 ➝ $50.00
6/23/2022BMO Capital MarketsInitiated CoverageOutperform$28.00
8/23/2021JPMorgan Chase & Co.Initiated CoverageOverweight$34.00
8/23/2021CowenInitiated CoverageOutperform
8/23/2021Piper SandlerInitiated CoverageOverweight$40.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.71 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 28 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
5/8/2025
  • 36 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/7/2025
  • 13 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 15 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 30 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 17 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 22 very positive mentions
  • 17 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
Mentions as of
11/4/2025
  • 29 very positive mentions
  • 33 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 29 very positive mentions
  • 33 positive mentions
  • 2 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Nuvalent logo
Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $106.86
Low: $104.95
High: $108.04

50 Day Range

MA: $95.95
Low: $81.39
High: $110.73

52 Week Range

Now: $106.86
Low: $55.53
High: $112.88

Volume

423,049 shs

Average Volume

728,151 shs

Market Capitalization

$7.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31

Frequently Asked Questions

What sell-side analysts currently cover shares of Nuvalent?

The following Wall Street analysts have issued research reports on Nuvalent in the last twelve months: Barclays PLC, Canaccord Genuity Group Inc., Cantor Fitzgerald, Guggenheim, HC Wainwright, Leerink Partners, Piper Sandler, Raymond James Financial, Inc., Robert W. Baird, Stifel Nicolaus, The Goldman Sachs Group, Inc., Truist Financial Corporation, UBS Group AG, Wedbush, and Weiss Ratings.
View the latest analyst ratings for NUVL.

What is the current price target for Nuvalent?

0 Wall Street analysts have set twelve-month price targets for Nuvalent in the last year. Their average twelve-month price target is $137.86, suggesting a possible upside of 29.0%. Robert W. Baird has the highest price target set, predicting NUVL will reach $158.00 in the next twelve months. Raymond James Financial, Inc. has the lowest price target set, forecasting a price of $105.00 for Nuvalent in the next year.
View the latest price targets for NUVL.

What is the current consensus analyst rating for Nuvalent?

Nuvalent currently has 1 sell rating and 14 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for NUVL.

What other companies compete with Nuvalent?

Other companies that are similar to Nuvalent include Teva Pharmaceutical Industries, BioNTech, Genmab A/S, Revolution Medicines and Roivant Sciences. Learn More about companies similar to Nuvalent.

How do I contact Nuvalent's investor relations team?

The company's listed phone number is 857-357-7000 and its investor relations email address is [email protected]. The official website for Nuvalent is www.nuvalent.com. Learn More about contacing Nuvalent investor relations.